Steffen Thiel

Azanta Danmark A/S operates as biopharmaceutical company developing treatments for women's health indications and for orphan oncology. The firm develops protein therapeutics within oncology and infectious diseases. The company was founded by Martin N. Bonde, Jens Christian Jensenius, Steffen Thiel, and R. Alan B. Ezekowitz in 2000 and is headquartered in Valby, Denmark.

Minervax ApS provides vaccine against streptococci. It utilizes fusion protein, which has proved to elicit good protective immunity. Its vaccine provides protective immunity against many clinically relevant GBS strains. The firm is engages in biotechnology, scientific and technical activities, and research and development. The company was founded in 2010 and is headquartered in Copenhagen, Denmark.

2cureX ApS develops and manufactures drugs and technology for the treatment of cancer. Its ChemoCellomics, integrates synthesis of compound libraries with throughput screening (HTS) in primary cells from patients. The company was founded by Ole Thastrup, Timm Jessen, and Grith Hagel in 2006 and is headquartered in Birkerod, Denmark.

Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark.

OncoNOx ApS provides drugs for the treatment of autoimmune diseases and cancer. It is a pharmaceutical company that transforms marketed drugs into proprietary molecules with anti-cancer and/or anti-inflammatory properties. The firm's projects include OX1001 and OX27-NO is a potent anti-cancer compounds in vitro and in vivo and are intended for the treatment of cancer, and OX1001 also exhibits anti-viral activity and is in development for treatment of human immunodeficiency virus (HIV) and acquired immune deficiency syndrome patients with or without HIV related cancer. The company was founded by Ferdinando Nicoletti, Gianni Garotta, Yousef Al-Abed, Marco Donia, and Mai-Britt Zocca in 2011 and is headquartered in Copenhagen, Denmark.

Asiros A/S manufactures bioactive based food ingredients and formulation. Its products include BerryShield berry powders used to manufacture berry powders and MitoActive products are based on the discovery of a bioactive compound in certain varieties of red- and blackcurrants. The comapny was founded in 2007 and is headquartered in Copenhagen, Denmark.

SEED Capital Management I/S is an Independent Venture Capital firm founded in 2004. The company is headquartered in Copenhagen, Denmark.

CytoTrack ApS engages in the provision of medical scanners for rare cell detection systems. Its products include CytoTrack CT11 scanner, CytoDisk and CytoCover, and CytoTrack reagent kit. The company was founded by Christian Caspersen, Tom Hede Markussen and Lars Ulrik Nielsen in 2004 and is headquartered in Lyngby, Denmark.

FluimediX ApS provides diagnostic system capable of deoxyribonucleic acid based species determination. Its product, called NanoCycler, delivers an identification of the presence of patogen species, based on their unique DNA 'fingerprint'. The firm markets its product for the use of the dairy production industry. It also collaborates with others in the fields of engineering, microtechnology, and surface analysis. The company was founded by Tomas Ussing in 2003 and is headquartered in Taastrup, Denmark.

Mirrx Therapeutics A/S provides protein production technology. Its technology Blockmirs, is steric antisense blockers that bind to specific microRNA binding sites in target RNAs to thereby prevent microRNA binding to the same site. The company was founded by Hans Thorleif Møller on July 1, 2009 and is headquartered in Vejle, Denmark.

BKG Pharma ApS develops and commercializes novel antibiotics against multidrug-resistant bacteria. It conducts research and development on treatment for multi-resistant infections such as resistance to chemotherapy. The company was founded by Birgit K. Giwercman in 2004 and is headquartered in Copenhagen, Denmark.